Detalles de la búsqueda
1.
The environmental impact of pharmaceuticals in Italy: Integrating healthcare and eco-toxicological data to assess and potentially mitigate their diffusion to water supplies.
Br J Clin Pharmacol;
89(7): 2020-2027, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37118883
2.
Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study.
Psychiatry Clin Neurosci;
77(3): 160-167, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36436204
3.
Impulse Control Disorders by Dopamine Partial Agonists: A Pharmacovigilance-Pharmacodynamic Assessment Through the FDA Adverse Event Reporting System.
Int J Neuropsychopharmacol;
25(9): 727-736, 2022 09 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-35639870
4.
Bone fracture as a novel immune-related adverse event with immune checkpoint inhibitors: Case series and large-scale pharmacovigilance analysis.
Int J Cancer;
149(3): 675-683, 2021 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33844854
5.
Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment.
Breast Cancer Res Treat;
186(1): 219-227, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33150548
6.
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19.
Br J Clin Pharmacol;
87(3): 1533-1540, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32639062
7.
Enhancing Transparency in Defining Studied Drugs: The Open-Source Living DiAna Dictionary for Standardizing Drug Names in the FAERS.
Drug Saf;
47(3): 271-284, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38175395
8.
Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System.
Target Oncol;
19(3): 435-445, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38696126
9.
The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement.
Drug Saf;
47(6): 575-584, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38713346
10.
The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration.
Drug Saf;
47(6): 585-599, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38713347
11.
Behavioral excess and disruptive conduct: A historical and taxonomic approach to the origin of the 'impulse control disorders' diagnostic construct.
Addiction;
118(4): 763-770, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36370093
12.
Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.
Drug Saf;
46(9): 819-833, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37341925
13.
Deliberate Self-Poisoning: Real-Time Characterization of Suicidal Habits and Toxidromes in the Food and Drug Administration Adverse Event Reporting System.
Drug Saf;
46(3): 283-295, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36689131
14.
Assessment of Reported Adverse Events After Interchanging Between TNF-α Inhibitor Biosimilars in the WHO Pharmacovigilance Database.
BioDrugs;
37(5): 699-707, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37278971
15.
Identifying Medications Underlying Communication Atypicalities in Psychotic and Affective Disorders: A Pharmacovigilance Study Within the FDA Adverse Event Reporting System.
J Speech Lang Hear Res;
66(9): 3242-3259, 2023 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-37524118
16.
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors.
JTO Clin Res Rep;
4(9): 100563, 2023 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-37745898
17.
Mapping Strategies to Assess and Increase the Validity of Published Disproportionality Signals: A Meta-Research Study.
Drug Saf;
46(9): 857-866, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37421568
18.
Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System.
Am J Clin Dermatol;
23(2): 247-255, 2022 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-34699032
19.
Crystal nephropathy and amoxicillin: insights from international spontaneous reporting systems.
J Nephrol;
35(3): 1017-1027, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34762277
20.
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
Target Oncol;
17(1): 43-51, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35025076